Endo180 protein expression was assessed by IHC using the anti-Endo180 mAb 39.10 (Fig. 1A) in rhabdomyosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, and undifferentiated pleomorphic sarcoma (UPS) TMAs (Fig. 1B and C; Supplementary Fig. S1). This evidence concerns the gene MRC2 and liposarcoma.